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ABSTRACT  
Diabetes mellitus is rising globally touching more than 180 million people worldwide. This is prevailing mostly in type 2 diabetes and according 
to WHO report the incidence is likely to be more than doubled by 2030. α-glucosidase inhibitors work by reducing the amount of glucose that 
the intestines absorb from food. In our previous work, forty-five benzimidazoles analogues were studied using 3D QSAR, HQSAR, and 
Pharmacophore mapping and based on their results 60 compounds were designed. Docking studies of those designed compounds showed that 
most of the compounds are bonding with important amino acids LEU 520, ARG 335 and ASP 69 through hydrogen bonds and steric interaction. 
In this work, synthesis of eleven compounds was done on the basis of molecular docking studies. Compounds containing hydroxyl and alkyl 
groups (compound no. 3, 9 and 10) were found to be five to eight folds more active with IC90 values in the range of 6.02 ± 1.10 to 33.25 ± 1.20 
µg/ml, in comparison with the standard drug, Acarbose (IC90= 290.55 ± 0.081 µg/ml). Thus, these compounds after the toxicity studies could be 
of therapeutic use in treating diabetes. 
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INTRODUCTION 
Diabetes mellitus is a persistent metabolic disorder 
diagnosed by hyperglycemia, glycosuria, hyperlipidemia, 
negative nitrogen balance and sometimes ketonaemia. Over 
18 years of age the international occurrence of diabetes 
among adults has ascended from 4.7% in 1980 to 8.5% in 
2014 (Global report on diabetes. WHO, Geneva, 2016). In 
2030 diabetes would be the seventh leading cause of death 
as per the World Health Organization (WHO) (Mathers CD, 
Loncar D, 2006). The effects of diabetes mellitus include long 
term damage, dysfunction and of various organs. Adult-onset 
blindness, lower limb amputations and kidney failure are the 
major outcomes of diabetes (Alberti K, Zimmet Z.1999). 
A common and severe difficulty confronted by many people 
with type 2 diabetes is postprandial hyperglycemia, α-
glucosidase inhibitors (AGIs) are well suited for its 
treatment (Vats Rajesh.2005). Furthermore, α-glucosidase 
may also be used as therapeutic target for other 
carbohydrate mediated diseases including cancer, HIV and 
hepatitis. Alpha-glucosidase is located in the brush border of 
the small intestine that acts upon 1, 4- alpha bonds. Most of 
the carbohydrates are present as oligo- or poly- saccharides, 
and have to be broken down to disaccharides, before 
sucrose, isomaltase, maltase, glycol-amylase, and lactase 
break them into digestible mono-saccharides (Kalra S., 
2014). AGIs inhibits both alpha amylase and the other α-
glucosidases, thus preventing absorption of starch and other 
carbohydrates from the brush border of the intestine. 
Benzo-hydrazides had been reported to possess various 
biological activities, which includes anti-leishmanial  (Taha 
et al., 2014b), anti-oxidant  (Aziz et al., 2014, Khan et al., 
2012), anti-glycation (Khan et al., 2013a, Khan et al., 
2013b, Khan et al., 2015, Jamil et al., 2015), anti-
bacterial  (Imran et al., 2014), and α-glucosidase inhibition 
(Taha et al., 2015f) activities. Benz-imidazole nucleus is an 
important pharmacophore with unique chemical and 
biological properties. Benzimidazoles have been found to 
possess anti-inflammatory (Kohno T, et. al. 1990), anti-
diabetic (Bhise UN, et. al. 2008), antispasmodic (Francisco 
AC, et. al. 2006), diuretics (Pashinski VG, et. al. 1978), 
analgesic (Kohno T, et. al. 1990), antimicrobial (Durmaz R, 
et. al. 2003), anti-helminthic (Solominova PS, et. al. 2004), 
anti-HIV (Gardiner JM, et. al. 1995), antiulcer (Bariwal JB, 
2008), anticancer (Gellis A, et. al. 2008), and anticonvulsant 
activities (Chimrri A, et al. 2001). 
Furthermore, recent studies have shown that some 
benzimidazole derivatives have been identified to exhibit α-
glucosidase inhibitory activity. In our work, we have 
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combined benzohydrazide and benz-imidazole nucleus, and 
developed SAR based on 3D-QSAR, HQSAR studies and 
Pharmacophore Mapping. Further from docking results, 11 
compounds were synthesized based on their dock scores. 
The synthesized compounds were tested for their in vitro α-
glucosidase inhibitory activity.  
EXPERIMENTAL 
Chemistry 
Melting points were determined by Veego model VMP-D 
melting point apparatus and were uncorrected. Thin layer 
chromatography was performed on precoated silica gel-G 
(0.2 mm thick) using different solvent system (petroleum 
ether: acetone 7:3, n-hexane: ethyl acetate 5:5) to ascertain 
the purity of the synthesized compounds. UV light and iodine 
vapors were used as the detecting agents. Infrared spectrum 
was taken on FT-IR-SP 10 STD at School of Chemical 
Sciences, Devi Ahilya Vishwavidyalaya, Indore. 1H-NMR and 
13C-NMR spectrums were obtained on Bruker DRX-400 (400 
MHz FT-NMR) at sophisticated analytical instrument facility, 
Panjab University, Chandigarh. Mass spectrum were 
obtained on Water UPLC-TQD (electron ionization spray and 
ACPI-MS) at sophisticated analytical instrument facility, 
CDRI, Lucknow. 
General Procedure for the Synthesis of Compounds 1-11 
Initially 0.001 moles of o-phenylenediamine (for first five 
compounds) and 2, 3-diamino naphthalene (for next six 
compounds) was taken into a round bottom flask and to it 
methyl-4-formyl benzoate (0.001 moles) was added. Ceric 
ammonium nitrate and hydrogen peroxide in catalytic 
amount was carefully added to the above mixture. This 
mixture was carefully assembled over heating mantle 
maintained at 50 ᵒC. The TLC was taken at the regular 
interval and it is observed that the completion of reaction 
took 60 min. The reaction mixture was allowed to dry at 
room temperature. This intermediate product (IM 1) was 
taken into next step. 
The intermediate was purified and 0.001 mole was taken in 
a round bottom flask, hydrazine hydrate (10 ml, 95%) was 
added to it along with 25 ml of ethanol and magnetically 
stirred for 9 h maintaining a temperature of 120 ᵒC. the 
completion of reaction is confirmed by TLC. This reaction 
mixture was allowed to cool at room temperature, to this 
mixture ice cold water added and filtered. The intermediate 
formed was collected on Whatmann filter paper, which was 
further purified and crystallized using n-hexane and 
methanol. This intermediate (IM 2) was then taken into next 
step. 
To this intermediate different benzaldehydes were added 
(equimolar) into round bottom flask and to this mixture, 
glacial acetic acid in catalytic amount was added and to this 
mixture 1-butanol (25 ml) was added. This mixture was 
again refluxed for 3 h. The completion of reaction was 
confirmed by TLC. The obtained mixture was allowed to cool 
at room temperature; ice cold water was added to the 
mixture and the obtained product was filtered using 
Whatmann filter paper and collected product was dried, 
recrystallized and purified by using n-hexane and ethanol. 
The obtained product was allowed to air dry (Panda et. al. 
2016, Taha et al. 2015, Rostamizadeh S et al.2009, Kiumars 
Bahrami.2008). 
(E)-N’-(4-diethylamino) benzlidene)-4-(1H-benzo[d] 
imidazol-2-yl)benzohydrazide 
Yield 97.83%; M.P. 275-276 ᵒC; FTIR (KBr) 3422 (NH of 
hydrazide), 3197 (NH of imidazole), 1680 (C=O), 1591, 1567 
(NH bend.), 1354, 1311, 1291 (C-N), 1073 (N-N), 861, 835 
(p-disubstituted rings); 1H-NMR (400 MHz, DMSO) δ ppm: δ 
11.6 ppm (s, 1H, NH), δ 8.34 ppm (s, 1H, CH=N), δ 6.68-8.32 
(m, 13H, Ar-H), δ 1.0-1.11 (m, 6H, CH3), δ 3.33-3.38 (m, 4H, 
CH2); 13C-NMRδ 161.97 (C=O), δ 148.98 (C=N), δ 43.69 
(CH2), δ 12.39 (CH3), δ 150.29 (N-C), δ 111.05-134.59 (Ar-C); 
MS (ESI): m/z 412.3(M+H)+. 
(E)-N’-(4-isopropylbenzlidene)-4-(1H-
benzo[d]imidazol-2-yl) benzohydrazide 
Yield 80.3%; M.P. 280-282  ᵒC; FTIR (KBr) 3476 (NH of 
hydrazide), 3221 (NH OF imidazole), 3053 (CH3), 2870 
(=CH2 str.), 1682 (C=O), 1632 (NH bend.), 1613 (C=N), 1177 
(C-N), 1451-1511 (ring breathing), 1425 (CH2), 1365 (CH3), 
824 (p-disubs.), 764-666 (CH bend oop); 1H-NMR (400 MHz, 
DMSO) δppm:δ 13.1 ppm (s, 1H, NH), δ 11.93 ppm (s, 1H, 
CH=N),δ 7.22-8.48 (m, 13H, Ar-H), δ 1.18-1.21 (m, 6H, CH3), 
δ 2.98 (m, 1H, CH); 13C-δ 162.46 (C=O), δ 150.76 (C=N),δ 
33.35 (CH), δ 23.60 (CH3),δ 111.51-150.25 (Ar-C); MS (ESI): 
m/z 383.3(M+H)+. 
(E)-N’-(4-isopropylbenzlidene)-4-(1H-naphtho [2,3-
d]imidazol-2-yl)benzohydrazide 
Yield 65.48%; M.P.  275 ᵒC; FTIR (KBr) 3485 (NH of 
hydrazide), 3211 (NH of imidazole), 3053 (=CH str.), 2961 (-
CH3 str.), 1660 (C=O), 1628 (C=N bend.), 1612 (NH bend.), 
1173 (C-N str.), 1449-1511 (ring breathing), 1363 (CH3 
bend.), 1011-1289 (CH bend. In-plane), 827 (p-disubs. ring), 
708-856 (CH bend. oop); 1H-NMR (400 MHz, DMSO) δppm: δ 
13.15 ppm (s, 1H, NH), δ 11.97 ppm (s, 1H, CH=N), δ 7.31-
8.49 (m, 15H, Ar-H), δ 1.17-1.21 (m, 6H, CH3), δ 2.87-2.92 
(m, 1H, CH); 13C-δ 162.41 (C=O), δ 154.51 (C=N), δ 33.36 
(CH), δ 23.60 (CH3), δ 106.51-154.37 (Ar-C);MS (ESI): m/z 
433.3(M+H)+. 
(E)-4-(1H-benzo[d]imidazol-2-yl)-N’-((2-
hydroxynaphthalen-7-yl)methylene) benzohydrazide 
Yield 90.9%; M.P. 308-309 ᵒC; FTIR (KBr) 3253 (NH of 
hydrazide), 3070 (NH of imidazole), 1693 (C=O), 1623 
(C=N), 1595 (NH bend.), 1456-1498 (ring breathing), 1470 
(-CH2 bend.), 1324 (C-N str.), 1244 (C-O str.), 1020-1297 
(CH bend. In-plane), 814 (p-disubs. ring), 711-940 (CH bend. 
oop); 1H-NMR (400 MHz, DMSO) δppm: δ 12.82 ppm (s, 1H, 
NH), δ 9.93 ppm (s, 1H, CH=N), δ 7.53-8.41 (m, 10H, Ar-H), δ 
7.2-7.5 (m, 4H, Ar-H), δ 12.32 (m, 1H, OH); 13C-δ 172.01 
(C=O), δ 158.07 (C=N), δ 108.5-120.5 (Ar-C), δ 161.87 (OH), 
δ 122.52-150.18 (Ar-C); MS (ESI): m/z 407.3(M+H)+. 
(E)-N’-(3, 5-dimethoxybenzlidene)-4-(1H-benzo[d] 
imidazol-2-yl) benzohydrazide 
Yield 84%; M.P.  282 ᵒC; FTIR (KBr) 3407 (NH of hydrazide), 
3087 (NH of imidazole), 1660 (-C=O), 1616 (-C=N), 1587 
(NH bend.), 1459-1500 (ring breathing), 1337, 1372 (CH3 
bend.), 1305 (C-N str.), 1125-1281 (C-H bend. In-plane), 
1113, 1055 (C-O str.), 838 (p-disubs. ring), 855 (p-disubs. 
ring), 706-891 (C-H bend. oop); 1H-NMR (400 MHz, DMSO) 
δppm:δ 12.0 ppm (s, 1H, NH), δ 8.4 ppm (s, 1H, CH=N), δ 
6.58-8.35 (m, 12H, Ar-H), δ 3.79 (m, 6H, OCH3); 13C-δ 162.63 
(C=O), δ 160.68 (C=N), δ 55.29 (OCH3), δ 111.51-150.14 (Ar-
C); MS (ESI): m/z 401.3(M+H)+. 
(E)-N’-(2,5-dimethoxybenzlidene)-4-(1H-naphtho[2,3-d] 
imidazol-2-yl) benzohydrazide 
Yield 91.6%; M.P. 166-168 ᵒC; FTIR (KBr) 3154 (NH of 
hydrazide), 2827 (NH of imidazole), 1652 (-C=O), 1467-
1493 (ring breathing), 1361 (C-N str.), 1220.11, 1199.77 (C-
O str.), 1021-1277 (C-H bend. In-plane), 706-894 (C-H bend. 
oop); 1H-NMR (400 MHz, DMSO) δppm: δ 13.2 ppm (s, 1H, 
NH), δ 12.05 ppm (s, 1H, CH=N), δ 6.98-8.86 (m, 14H, Ar-H), 
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δ 3.76-3.82 (m, 6H, OCH3); 13C-δ 171.99 (C=O), δ 162.30 
(C=N), δ55.41-56.19 (OCH3), δ 109.21-154.37 (Ar-C);MS 
(ESI): m/z 451.3(M+H)+. 
(E)-N’-(3, 4, 5-trimethoxybenzlidene)-4-(1H-naphtho [2, 
3-d] imidazol-2-yl) benzohydrazide 
Yield 78%; M.P. 167 ᵒC; FTIR (KBr) 3503.31 (NH of 
hydrazide), 2947 (NH of Imidazole), 1707 (-C=O), 1614 (-
C=N), 1587 (NH bend.), 1461- 1551 (ring breathing), 1327 
(C-N str.), 1188-1276 (C-H bend. in-plane), 1125, 1108, 1125 
(-C-O str.), 827 (p-disubs. ring), 710-855 (C-H bend. oop); 
1H-NMR (400 MHz, DMSO) δppm:δ 13.17 ppm (s, 1H, NH), δ 
9.89 ppm (s, 1H, CH=N), δ 7.24-8.44 (m, 13H, Ar-H), δ 3.45 - 
3.90 (m, 9H, OCH3); 13C-δ 165.70 (C=O), δ 154.31 (C=N), δ 
52.26 (OCH3), δ 106.69 -154.07 (Ar-C);MS (ESI): m/z 
481.3(M+H)+. 
(E)-N’-(2, 4-dimethoxybenzlidene)-4-(1H-naphtho [2, 3-d] 
imidazol-2 yl) benzohydrazide 
Yield 84.8%; M.P. 289-291 ᵒC; FTIR (KBr) 3491.84 (NH for 
hydrazide), 3203 (NH of imidazole), 3080 and 3049 (-CH3 
str.), 1659 (-C=O), 1626 (C=N), 1601 (NH bend.), 1466-1520 
(ring breathing),1372 (-CH3 bend.), 1353 and 1311 (C-N 
str.), 1011-1289 (C-H bend. in-plane), 811 and 855 (p-
disubs. ring), 710-786 (C-H bend. oop);1H-NMR (400 MHz, 
DMSO) δppm:δ 13.12 ppm (s, 1H, NH), δ 11.84 ppm (s, 1H, 
CH=N), δ 6.63-8.77 (m, 12H, Ar-H), δ 3.45 - 3.90 (m, 6H, 
OCH3); 13C-δ 172.03 (C=O), δ 162.50 (C=N), δ 55.39 (OCH3), δ 
106.39 -159.21 (Ar-C);MS (ESI): m/z 401.3(M+H)+. 
(E)-N’-(4-(diethylamino) benzlidene)-4-(1H-naphtho [2, 3-
d] imidazol-2-yl) benzohydrazide 
Yield 64.20%; M.P. 203-205 ᵒC; FTIR (KBr) 3230.2 (NH of 
hydrazide), 3090 (NH of Imidazole), 3023 (CH3 str.), 2968, 
2941 and 2840 (CH str.), 1653 (C=O), 1631 (C=N), 1615 (NH 
bend.), 1450-1466 (ring breathing), 1243 (C-O str.), 1013-
1277 (CH bend. In-plane), 815, 839 (p-disubs. ring), 735-893 
(CH bend. oop); 1H-NMR (400 MHz, DMSO) δppm: δ 13.06 
ppm (s, 1H, NH), δ 11.64 ppm (s, 1H, CH=N), δ 6.58-8.38 (m, 
14H, Ar-H), δ 0.96-1.00 (m, 6H, CH3), δ 3.22-3.37 (m, 4H, 
CH2); 13C-δ 161.98 (C=O), δ 149.16 (C=N), δ43.67 (CH2), 
δ12.36 (CH3), δ 154.46 (N-C), δ 106.77-148.90 (Ar-C);MS 
(ESI): m/z 462.4 (M+H)+. 
(E)-N’-(2-hydroxy-3-ethoxybenzlidene)-4-(1H-
naphtho[2,3-d]imidazol-2-yl) benzohydrazide 
Yield 94.41%, M.P. 200ᵒC; FTIR (KBr) 3221 (NH of 
hydrazide), 3063 (NH of Imidazole), 1664(C=O), 1611(C=N), 
1555 (NH bend.), 1465 and 1491 (ring breathing), 1433 (C-
O-H bend.), 1357 (C-N str.), 1019-1308 (CH bend. In-plane), 
1130 (C-O str.), 838 (p-disubs. ring), 705- 893 (CH bend. 
oop); 1H-NMR (400 MHz, DMSO) δppm: δ 10.28 ppm (s, 1H, 
NH), δ 7.53-8.98 (m, 10H, Ar-H), δ 4.0 (m, 4H, OCH2), δ 10.28 
(m, 1H, OH), δ 1.3 ppm (m, 6H, CH3); 13C-δ 192.51 (C=O), δ 
166.81 (C=N), δ 64.3 (OCH2), δ 14.65 (CH3), δ 118.34-154.03 
(Ar-C);MS (ESI): m/z 451.3(M+H)+. 
(E)-N’-(2-hydroxy-3-ethoxybenzlidene)-4-(1H-
benzo[d]imidazol-2-yl) benzohydrazide 
Yield 91.44%; M.P. 272 ᵒC; FTIR (KBr) 3502 (NH of 
hydrazide), 3053 (NH of imidazole), 2963 (CH3 str.), 2925 
(CH str.), 1708 (C=O), 1615 (C=N), 1455-1468 (Ring 
breathing), 1275 (C-O-H bend.), 1071-1249 (CH in-plane 
bend.), 1109 (C-O str.), 1089 (C-N str.), 800-850 (p disubs. 
ring), 711-780 (CH oop bend.);1H-NMR (400 MHz, DMSO) 
δppm:δ 13.12 ppm (s, 1H, NH), δ 12.21 ppm (s, 1H, CH=N), δ 
7.14-8.36 (m, 6H, Ar-H), δ 4.0 (m, 4H, OCH2), δ 11.08 (m, 1H, 
OH), δ 1.3 ppm (m, 6H, CH3); 13C-δ 162.20 (C=O), δ 150.27 
(C=N), δ 14.70 (CH3), δ 148.87 (OH), 64.13 (CH2), δ 115.27-
147.58 (Ar-C);MS (ESI): m/z 401.3(M+H)+. 
Assay for α-Glucosidase Inhibitory Activity 
The α-glucosidase inhibition activity was carried out at 
School of Biochemistry, Devi Ahilya Vishwavidyalaya, 
Indore, M.P. Potassium dihydrogen phosphate (4.35 g) and 
3.55 g of disodium hydrogen phosphate was dissolved in 
100 ml distilled water and sufficient water was added to 
produce 500 ml of phosphate buffer pH 6.8, 50 mM. The 
substrate (p-Nitrophenyl-α-D-glucopyranoside) solution 0.7 
mM was prepared in buffer solution. 0.14 mg of the enzyme 
α-glucosidase. Test compounds 10 mg, 20 mg, 30 mg, 40 mg 
and 50 mg were dissolved in the DMSO and further dilutions 
were made with distilled water. Enzyme (20 µl), 20 µl of test 
samples and 135 µl of the buffer solution was added to the 
96-well plates. The solution was pre-incubated for 15 
minutes at 37 ᵒC. Instead of test samples 20 µl of DMSO is 
added in case of control (Zawawi et al. 2016). Substrate (25) 
was added and incubated for 30 min. After that the shaking 
of the 96-well plate is done for 15 s and absorbance was 
taken at 405 nm. All experiments were triplicated and the 
results were expressed as the percentage inhibition of three 
determinations. The enzyme inhibitory rates of samples 
were calculated as follows:  
Percentage inhibition = [(absorbance of control - absorbance 
of the test sample)/ absorbance of control] × 100 
RESULT AND DISCUSSION 
Chemistry 
 
 
Figure 1: Reaction conditions for synthesis of substituted benzimidazoles: (i) 30% hydrogen peroxide or ceric ammonium 
nitrate; (ii) hydrazine hydrate; (iii) substituted benzaldehyde. 
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The designed 11 benzimidazoles having different 
substitutions were synthesized from good to excellent yields. 
First intermediate (IM 1) was formed in oxidation reaction 
using ceric ammonium nitrate, the carbonyl carbon of the 
aldehyde was attacked by the nitrogen atom of either o-
phenylenediamine or 2, 3-diamino naphthalene followed by 
the removal of the water molecule, ring cyclization and 
oxidized in presence of ceric ammonium nitrate. In the 
intermediate so formed nucleophilic addition of the 
hydrazine moiety took place in the second step after the 
removal of methanol as good leaving group. This 
intermediate (IM 2) undergoes the Mannich reaction to form 
the final product in good yield as shown in Scheme 1. All 
these compounds (1-11) were characterized by 
spectroscopic methods (IR, NMR, and MS). 
Enzyme Inhibitory Studies 
The novel synthesized compounds were evaluated for the α-
glucosidase inhibitory activity using commercially available 
α-glucosidase inhibitor acarbose as positive control. 
Compounds 1, 3, 4, 6, 7, 9, 10 and 11 showed significant 
activity as compared with the standard drug acarbose. From 
these tested compounds, three compounds were found to be 
most active. Compound 9, 10 and 3 inhibited the enzyme α-
glucosidase by 90.84%, 78.67% and 89.96% respectively at 
the minimum dose concentration that is 10 µg/ml. The 
standard drug acarbose inhibited 55.95% of the enzyme α-
glucosidase at the same concentration. 
The most active analog among the series is 9 which was 
having benzyl group at R1 and 4-diethyl amino group at R2. 
The second most active compound is 10 which was having 
benzyl group at the R1 and 2-hydroxy-3-ethoxy at R2. 
Similarly, the third potent analog was 3 which was having 
benzyl group at the R1and 4-isopropyl group at R2. All these 
substituents resulted in hydrogen bonding with the crucial 
amino-acids having significant role in the activity. 
Based on the percentage inhibition results of these 
compounds the IC90 values were calculated by plotting the 
graph of the concentration versus the percentage inhibition 
of the enzymatic activity extrapolating the 90% inhibition to 
the concentration.  It was found that the IC90 value of the 
standard drug acarbose was found to be 290.55 ± 0.081 
µg/ml, and that of 9, 3 and 10 it was found at 6.02 ± 1.10 
µg/ml, 12.94 ± 1.41 µg/ml and 33.25 ± 1.20 µg/ml. 
The IC90 value of the synthesized compounds were found to 
be lower than the standard drug acarbose means they will 
have even less IC50 value concluding they could have a 
considerable inhibitory activity against the standard drug 
acarbose.  
On the basis of the in vitro activity of the α-glucosidase 
inhibition it was found that nearly all compounds were more 
potent than standard drug acarbose so further these 
compounds can be proceeded for the toxicity studies and 
pharmacodynamics studies. 
 
Table 1. α-glucosidase inhibitory activity of benzohydrazide benzimidazoles derivatives (1-11). 
HN
O
N
N
H
N
R
 
 
3*, 6*, 7*, 8*, 9*, 10* 
 
 
1, 2, 4, 5, 11 
Compound R % Inhibition (Mean ± SEM) 
1 4-diethyl amino benzylidene 90.58 ± 0.40 
2 4-isopropyl benzylidene 82.93 ± 1.24 
3* 4-isopropyl benzylidene 95.48 ± 1.10 
4 2-hydroxy naphthalene 96.66 ± 0.10 
5 3,5-dimethoxy benzylidene 84.56 ± 1.10 
6 2,5-dimethoxy benzylidene 84.31 ± 0.60 
7* 3,4,5-trimethoxy benzylidene 81.05 ± 2.60 
8* 2,4-dimethoxy benzylidene 82.68 ± 0.10 
9* 4-diethyl amino benzylidene 98.26 ± 0.65 
10* 2-hydroxy-3-ethoxy benzylidene 93.72 ± 0.35 
11 2-hydroxy-3-ethoxy benzylidene 86.44 ± 0.42 
Standard drug Acarbose 72.54 ± 0 .81 
 
 
 
 
HN
O
N
N
H
N
R
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Molecular Docking 
In compound 9, the tertiary amino group was one of the 
strong electron donating and also contributed in formation 
of hydrogen bond with amino acid Glu 332 which was found 
to be very important for the activity.  
 
 
   
Figure 2. Docking pose of compound 9, 10 and 3 in the active site. 
 
The second most active compound 10 had a benzyl group at 
R1 and 2-hydroxy-3-ethoxy at R2. The hydroxyl and alkoxy 
groups were individually among the strong electron 
donating groups and also contribute to the important 
interactions with the active site of enzyme. Arg 335 was 
found to be critical for the binding of the substrate at the 
active site of enzyme and Asp 519 forms hydrogen bond at 
the distance between 2.7-2.5 Aᵒ with the enzyme. Compound 
3 had a benzyl group at R1 and 4-isopropyl at R2. 4-isopropyl 
was considered to be weak electron donating group but 
formed hydrogen bond with the oxygen molecule of the 
amino acid residue Asp 69. It was observed that the 
marketed α-glucosidase inhibitors were bulky molecules. 
The cavity of the active site should be large that might be the 
reason for the increased activity of the naphtho-imidazoles 
than benzimidazoles. It can be concluded that the 
hypotheses of the SAR made from computational studies 
was found to be correct as per the in vitro activity results. A 
bulky group should be placed at R1 and stronger electron 
donating group needs to be substituted at R2 for enhanced α-
glucosidase inhibitory activity. 
 
Table 11: Docking score of designed compounds. 
S.N. R 
Total 
score 
Crash  Polar  D score 
PMF 
score 
G score 
ChemSco
re  
CS 
score 
1. 3,4-OC2H5 3.81  -6.24 2.44 -193.62 -152.33 -241.75 -39.03 1 
2. 3-ethoxy-4-hydroxy 4.40 -2.45 4.24 -146.21 -158.65 -209.26 -33.30 1 
3. 4-dimethyl amino 2.77   -1.28 0.93 -134.45 -61.370 -188.77 -30.48 1 
4. 4-diethyl amino 5.31  -2.59 0.01 -183.44 -110.25 -260.77 32.54 2 
5. 4-ethyl 4.20  -2.10 0.70 -143.07 -114.35 -255.61 -28.42 0 
6. 2,5-dimethoxy 5.53  -2.34 1.54 -172.44 -159.95 -176.77 -31.97 3 
7. 2,4-dimethoxy 4.63  -5.02 1.64 -199.71 -152.83 -270.99 -39.55 1 
8. 2-ethoxy-4-hydroxy 5.53  -4.12 2.71 -196.27 -153.80 -237.78 -43.27 1 
9. 2-hydroxy-3-methoxy 5.10  -5.26 4.19 -191.03 -160.26 -295.48 -42.86 0 
10. 3-ethoxy-2-hydroxy 5.03  -4.32 1.22 -207.77 -160.03 -315.82 -35.14 0 
11. 3,4,5- trimethoxy 5.47  -2.57 2.01   -190.93 -77.444 -247.700 -34.3814 0 
12. 4-isopropyl 5.78  -2.27 0.001 -165.30 -103.38 -256.098 -31.4411 1 
13. 4-acetamido 3.89    -1.53 1.49 -143.93 -107.27 -196.830 -27.3129 2 
14. 2,6- dimethoxy 2.41  -2.80 0.0001 -180.18 -135.46 -267.256 -33.3888 1 
15. 4-hydroxy-2-methoxy 4.51  -5.71 3.2449 -193.29 -150.07 -271.467 -42.2919 0 
16. 2-hydroxy-6-methoxy 4.67  -4.21 1.5344 -202.13 -140.97 -288.026 -34.6364 1 
17. 2,3-dimethoxy 4.99  -1.79 1.08 -158.54 -119.97 -199.31 -30.44 0 
18. 2,3,4- trimethoxy 3.05   -6.25 1.46 -208.62 -176.35 -292.61 -35.25 3 
19. 3,5-dimethoxy 6.81  -5.34 -2.73 -213.70 -169.8 -299.4 -44.16 1 
20. 2,4,6- trimethoxy 3.95   -5.32 6.65 -175.80 -182.48 -292.39 -43.23 3 
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21. 1-methoxy naphthalene 2.30   -4.59 1.09 -163.26 -84.639 -227.51 -36.62 1 
22. 2-methoxy naphthalene 2.93  -4.06 0.02 -235.77 -56.110 -301.99 -59.72 2 
23. 2-ethoxy naphthalene 2.40   -4.15 1.79 -184.36 -85.596 -269.44 -43.11 2 
24. 2-hydroxy naphthalene 4.48   -3.87 1.21 -208.84 -6.0921 -327.25 -53.92 1 
25. 1, 4-dimethoxy naphthalene 3.03  -4.20 0.91 -197.77 -116.78 -253.07 -40.56 2 
26. 1-indol-2-yl 3.82    -7.31 4.04 -185.33 -138.15 -275.25 -45.22 2 
27. 4-ethylthiophen-2-yl 4.41   -3.77 1.87 -181.85 -8.7379 -254.40 -44.54 1 
28. Quinolin-3-yl 4.87  -1.75 0.04 -165.85 -114.18 -240.56 -31.44 2 
29. 2-hydroxy-4-methoxy 4.87   -2.36 3.59 -169.39 -181.02 -227.96 -35.82 0 
30. 3,4,5- trimethoxy 3.22    -3.00 0.03 -174.48 -106.45 -212.32 -25.58 0 
31.* 3,4-OC2H5 5.97    -3.01 0.06 -189.57 -146.58 -247.28 -29.09 3 
32.* 3-ethoxy-4-hydroxy 4.18   -5.25 3.85 -173.60 -165.93 -243.86 -37.08 1 
33.* 4-dimethyl amino 5.25  -3.37 0 -152.04 -116.51 -270.76 -31.62 2 
34.* 4-diethyl amino 6.69   -2.43 0.19 -178.50 -115.03 -252.62 -29.47 4 
35.* 4-ethyl 4.87    -0.82 0.28 -143.55 -121.10 -219.30 -30.15 0 
36.* 2,5-dimethoxy 4.64    -3.74 0.92 -179.33 -147.07 -200.01 -29.57 3 
37.* 2,4-dimethoxy 5.34  -4.03 2.47 -186.16 -153.46 -219.65 -37.37 3 
38.* 2-ethoxy-4-hydroxy 4.76  -5.64 4.46 -186.19 -173.36 -307.90 -40.80 2 
39.* 2-hydroxy-3-methoxy 5.07   -2.91 1.93 -176.96 -160.67 -243.93 -33.93 0 
40.* 3-ethoxy-2-hydroxy 4.47    -4.52 1.18 -191.29 -156.10 -304.55 -30.38 2 
41.* 3,4,5- trimethoxy 5.15     -4.94 3.13 -181.05 -95.176 -276.14 -40.44 2 
42.* 4-isopropyl 5.88  -1.60 0.01 -162.37 -99.421 -268.22 -30.47 2 
43.* 4-acetamido 3.86   -1.64 0.089 -156.27 -125.77 -229.04 -28.04 4 
44.* 2,5- dimethoxy 6.08     -1.13 1.24 -147.49 -136.61 -174.16 -32.08  4 
45.* 4-hydroxy-2-methoxy 5.98    -2.76 1.42 -175.23 -157.46 -274.95 -31.85 1 
46.* 2-hydroxy-6-methoxy 5.45   -3.47 3.89 -179.01 -180.18 -225.42 -39.15 4 
47.* 2,3-dimethoxy 6.43   -1.16 1.85 -150.56 -56.386 -203.44 -30.82 3 
48.* 2,3,4- trimethoxy 4.44   -2.06 1.14 -162.98 -140.08 -191.51 -33.43 5 
49.* 3,5-dimethoxy 5.67    -1.42 0.24 -150.44 -125.93 -192.15 -29.73 0 
50.* 2,4,6- trimethoxy 5.88     -2.55 3.18 -168.55 -191.29 -227.57 -32.03 1 
51.* 1-methoxy naphthalene 4.49  -5.67 1.43 -175.35 -70.719 -251.55 -37.44 2 
52.* 2-methoxy naphthalene 5.60    -1.67 0.33 -161.26 -115.30 -252.93 -31.18 0 
53.* 2-ethoxy naphthalene 4.95   -3.38 1.17 -180.89 -114.44 -276.61 -38.52 4 
54.* 2-hydroxy naphthalene 5.70    -1.73 2.10 -160.00 -131.73 -243.35 -39.25 4 
55.* 1,4-dimethoxy naphthalene 5.36   -2.59 2.82 -167.87 -139.38 -217.17 -38.41 2 
56.* 1-indol-2-yl 6.65    -1.84 0.02 -163.33 -119.67 -263.51 -30.38 1 
57.* 4-ethylthiophen-2-yl 3.20    -4.36 1.11 -152.52 -119.87 -255.72 -31.19 1 
58.* Quinolin-3-yl 5.58    -1.52 2.07 -160.56 -134.22 -256.59 -32.76 2 
59.* 2-hydroxy-4-methoxy 5.29    -2.76 3.74 -160.00 -175.18 -193.79 -33.74 2 
60.* 3,4,5- trimethoxy 3.83    -2.72 0.013 -172.81 -137.03 -232.94 -26.83 0 
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CONCLUSION  
Eleven benzimidazoles derivatives had been synthesized and 
evaluated for their α-glucosidase inhibitory activities. Based 
on results obtained from docking and biological evaluation, 
benzyl group substitution on benzimidazole and electron 
donating groups like diethyl amino, hydroxyl played an 
important role in this activity as they were found to be five to 
eight folds more active as compared to standard drug 
Acarbose.  Compound 9, 10 and 3 bonding with significant 
amino acids LEU 520, ARG 335 and ASP 69 which were 
located at the entrance of active site pocket, and if they don’t 
move, the substrate cannot bind at the active site. It can 
further be concluded from the results that the good 
inhibitory activity of the compounds may be due to bulky 
substitution of benzimidazole ring and existence of electron 
donating group on R. 
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